-
Something wrong with this record ?
Procedural Safety and Device Performance of the PorticoTM Valve from Experienced TAVI Centers: 30-Day Outcomes in the Multicenter CONFIDENCE Registry
H. Mollmann, A. Linke, L. Nombela-Franco, M. Sluka, JFO. Dominguez, M. Montorfano, WK. Kim, M. Arnold, M. Vasa-Nicotera, L. Conradi, A. Camuglia, F. Bedogni, G. Manoharan
Language English Country Switzerland
Document type Journal Article
Grant support
NCT03752866
Abbott (United States)
NLK
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2019-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Health & Medicine (ProQuest)
from 2019-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
36013084
DOI
10.3390/jcm11164839
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
A total of 1001 subjects (82.0 years, 62.5% female, 63.7% NYHA III/IV at baseline) with severe aortic stenosis at high surgical risk were enrolled in the prospective CONFIDENCE registry and treated with a PorticoTM transcatheter heart valve (THV) using either a first-generation delivery system (DS) or the FlexNavTM DS. The objective of this registry is to characterize the procedural safety and device performance of the PorticoTM THV at 30 days. The study collected 'standard-of-care' clinical and device performance data, with adverse events adjudicated by an independent clinical event committee according to the Valve Academic Research Consortium-2 criteria. The implantation of a single PorticoTM THV was successful in 97.5% of subjects. The 30-day all-cause mortality, cardiovascular mortality, and disabling stroke rates were 2.6%, 2.1%, and 1.8%, respectively. A new pacemaker was implanted in 19.0% of subjects at 30 days. At 30 days, the effective orifice area and mean gradient values were 1.82 cm2 and 7.1 mmHg, respectively. The 30-day rate of moderate paravalvular leak (PVL) was 2.1%, with no occurrence of severe PVL. The PorticoTM THV demonstrated improved hemodynamic performance and low rates of safety events at 30 days in a large cohort of subjects implanted with the PorticoTM THV with either the first-generation DS or FlexNavTM DS.
Department of Cardiology Friedrich Alexander Universität Erlangen Nuremberg 91054 Erlangen Germany
Department of Cardiology IRCCS Policlinico San Donato 20097 Milan Italy
Department of Cardiology Royal Victoria Hospital Belfast BT12 6BA UK
Department of Cardiology St Johannes Hospital 44137 Dortmund Germany
Department of Cardiology The Wesley Hospital Brisbane QLD 4066 Australia
Department of Cardiology University of Queensland Brisbane QLD 4072 Australia
Department of Cardiovascular Surgery University Heart and Vascular Center 20251 Hamburg Germany
Department of Medicine Cardiology University Hospital Olomouc 779 00 Olomouc Czech Republic
Interventional Cardiology Unit Hospital Universitario Puerta de Hierro Hospital 28222 Madrid Spain
Interventional Cardiology Unit IRCCS Ospedale San Raffaele 20132 Milan Italy
Kerckhoff Heart and Thorax Centre 61231 Bad Nauheim Germany
Klinikum der Johann Wolfgang Goethe Universitaet Frankfurt 60596 Frankfurt Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023499
- 003
- CZ-PrNML
- 005
- 20221031095211.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/jcm11164839 $2 doi
- 035 __
- $a (PubMed)36013084
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Mollmann, Helge $u Department of Cardiology, St. Johannes Hospital, 44137 Dortmund, Germany
- 245 10
- $a Procedural Safety and Device Performance of the PorticoTM Valve from Experienced TAVI Centers: 30-Day Outcomes in the Multicenter CONFIDENCE Registry / $c H. Mollmann, A. Linke, L. Nombela-Franco, M. Sluka, JFO. Dominguez, M. Montorfano, WK. Kim, M. Arnold, M. Vasa-Nicotera, L. Conradi, A. Camuglia, F. Bedogni, G. Manoharan
- 520 9_
- $a A total of 1001 subjects (82.0 years, 62.5% female, 63.7% NYHA III/IV at baseline) with severe aortic stenosis at high surgical risk were enrolled in the prospective CONFIDENCE registry and treated with a PorticoTM transcatheter heart valve (THV) using either a first-generation delivery system (DS) or the FlexNavTM DS. The objective of this registry is to characterize the procedural safety and device performance of the PorticoTM THV at 30 days. The study collected 'standard-of-care' clinical and device performance data, with adverse events adjudicated by an independent clinical event committee according to the Valve Academic Research Consortium-2 criteria. The implantation of a single PorticoTM THV was successful in 97.5% of subjects. The 30-day all-cause mortality, cardiovascular mortality, and disabling stroke rates were 2.6%, 2.1%, and 1.8%, respectively. A new pacemaker was implanted in 19.0% of subjects at 30 days. At 30 days, the effective orifice area and mean gradient values were 1.82 cm2 and 7.1 mmHg, respectively. The 30-day rate of moderate paravalvular leak (PVL) was 2.1%, with no occurrence of severe PVL. The PorticoTM THV demonstrated improved hemodynamic performance and low rates of safety events at 30 days in a large cohort of subjects implanted with the PorticoTM THV with either the first-generation DS or FlexNavTM DS.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Linke, Axel $u Klinik für Innere Medizin/Kardiologie, Universitätsklinik Technische Universität Dresden, Herzzentrum Dresden Fetscherstraße 76, 01307 Dresden, Germany
- 700 1_
- $a Nombela-Franco, Luis $u Cardiovascular Institute, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
- 700 1_
- $a Sluka, Martin $u Department of Medicine-Cardiology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $1 0000000226255445
- 700 1_
- $a Dominguez, Juan Francisco Oteo $u Interventional Cardiology Unit, Hospital Universitario Puerta de Hierro Hospital, 28222 Madrid, Spain $1 0000000226414135
- 700 1_
- $a Montorfano, Matteo $u Interventional Cardiology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
- 700 1_
- $a Kim, Won-Keun $u Kerckhoff Heart and Thorax Centre, 61231 Bad Nauheim, Germany
- 700 1_
- $a Arnold, Martin $u Department of Cardiology, Friedrich Alexander Universität Erlangen-Nuremberg, 91054 Erlangen, Germany
- 700 1_
- $a Vasa-Nicotera, Mariuca $u Klinikum der Johann Wolfgang Goethe Universitaet Frankfurt, 60596 Frankfurt, Germany
- 700 1_
- $a Conradi, Lenard $u Department of Cardiovascular Surgery, University Heart and Vascular Center, 20251 Hamburg, Germany
- 700 1_
- $a Camuglia, Anthony $u Department of Cardiology, University of Queensland, Brisbane, QLD 4072, Australia $u Department of Cardiology, The Wesley Hospital, Brisbane, QLD 4066, Australia $1 0000000184353986
- 700 1_
- $a Bedogni, Francesco $u Department of Cardiology, IRCCS Policlinico San Donato, 20097 Milan, Italy
- 700 1_
- $a Manoharan, Ganesh $u Department of Cardiology, Royal Victoria Hospital, Belfast BT12 6BA, UK
- 773 0_
- $w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 11, č. 16 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36013084 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095209 $b ABA008
- 999 __
- $a ind $b bmc $g 1853888 $s 1174787
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 11 $c 16 $e 20220818 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
- GRA __
- $a NCT03752866 $p Abbott (United States)
- LZP __
- $a Pubmed-20221010